Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Thoracic 2Genitourinary 2Plasma cell 1Dermatologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm, Residual 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × tetrathiomolybdate × Breast × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT00195091 2025-05-16

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
16 enrolled 5 charts
Breast

Breast Neoplasms

NCT00674557 2013-07-10

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
111 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡